Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Y-90 in Advanced HCC
NCT02837029Phase 1Completed
- Sponsor
- Northwestern University
- Start
- Jul 2016
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab in hepatocellular carcinoma (HCC), sponsored by Northwestern University. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jul 2016; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02837029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02837029.